Blue Cross Blue Shield now requires Oklahomans receive prior approval for severe asthma drugs
Patients in five states who have severe asthma and are covered by Blue Cross Blue Shield are facing a new obstacle to getting treatment.
On Tuesday, BCBS began mandating that severe asthma patients self-administer their drugs at home, unless their provider gets prior approval from the insurance company.
The patients affected are those covered in Illinois, Texas, Oklahoma, New Mexico, and Montana, but not those with Medicare or Medicaid, the insurance giant says.
Given as injections, the treatments in question are Fasenra (benralizumab), Tezspire (tezepelumab), Nucala (mepolizumab) and Xolair (omalizumab). All belong to a class of drugs known as biologics.
The decision is expected to affect thousands of patients. It's estimated that between 5% and 10% of asthma patients have severe asthma, characterized by more flare-ups and hospitalizations. In Illinois, for example, about 860,000 patients have asthma, according to the federal Centers for Disease Control and Prevention. That means between 43,000 and 86,000 of them have severe asthma.
Clinics already have loads of prior authorizations to process that often delay care, said Dr. Priya Bansal, a pediatrician and asthma and allergy physician in Illinois. Her practice sees many rural patients and those with chronic disease.
'On any given day, we'll have anywhere from 30, to my highest was 130,' she said.
The change interferes with a provider and patient decision on whether in-office or at-home treatment is best for the patient, Bansal said.
'That decision that's supposed to go on between the physician and the patient is getting taken away,' she said. 'If I have a pediatric food allergy patient and they want to get the medication in the clinic, I want to be able to have the flexibility to do that.'
The sickest asthma patients are often on biologics, explained Dr. Bridgette Jones, past chair of the American Academy of Pediatrics' drug committee and the American Academy of Allergy Asthma and Immunology's asthma cough diagnosis and treatment panel.
'These are the patients that have failed at other therapies,' said Jones, a pediatric allergy and immunology physician at Children's Mercy Hospital in Missouri. 'Once you're getting to a biologic, it means that your asthma is not under control, having frequent flare-ups.'
Black and Indigenous adults and children, as well as Puerto Rican people have higher rates of illness and less access to care.
For people who suffer from severe asthma, the typical inhaler is often not enough. The affected drugs can help manage severe, uncontrolled asthma by reducing airway inflammation,
While the drugs are approved by the U.S. Food and Drug Administration for self-injecting at home, they also come with risks for the uncommon but life-threatening anaphylaxis.
That's why providers typically start patients on these drugs in-office for monitoring.
But for at least one of the drugs, Xolair, the reaction can also happen up to a year into treatment.
Many families are not comfortable administering biologics to their kids with severe asthma, Jones said.
Clinics serving higher-need or underserved populations may often lack the resources to deal with more prior approvals, she added.
A recent study by Massachusetts General Hospital and funded by Amgen, which developed Tezspire with AstraZeneca, suggested that in some states, the percentage of asthma patients with severe asthma is higher than 10%. In Texas, for example, about 23% of severe persistent asthma had severe uncontrolled disease.
Stateline reporter Nada Hassanein can be reached at nhassanein@stateline.org.
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
SUPPORT: YOU MAKE OUR WORK POSSIBLE
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
4 hours ago
- Time Business News
Navigating DME Billing Audits: Best Practices for Providers
Durable medical equipment (DME) suppliers and provider offices face an increasingly scrutinized reimbursement environment. Audits — whether from Recovery Audit Contractors (RACs), Medicare Administrative Contractors (MACs), Office of Inspector General (OIG), or private payers — target documentation gaps, improper enrollment, billing mistakes, and non-compliance with DMEPOS supplier standards. This article gives providers an actionable roadmap to reduce risk, respond effectively when audited, and build durable compliance processes. Medicare and related programs continue to refine oversight of DME claims. Recent updates to the DMEPOS quality standards, continuing OIG findings of improper payments, and active MAC/RAC programs mean that suppliers who rely on old processes risk costly recoupments and loss of billing privileges. Staying current with CMS guidance and audit trends is not optional — it's central to financial and regulatory health. Understanding what draws attention helps you prioritize controls. Typical triggers include: Missing or incomplete Standard Written Orders (SWOs) and supporting medical records. Inadequate proof of delivery (POD) or beneficiary authorization. Non-compliance with updated DMEPOS supplier standards (accreditation, patient training, servicing). Incorrect coding, units, or billing for items excluded by the Master List or specific policy. Billing during inpatient stays or hospice periods when Medicare rules prohibit payment — a frequent OIG finding. Preventing large-scale recoupments starts with pragmatic, repeatable controls you can implement today. Tighten enrollment and supplier credentials. Maintain current PECOS enrollment, NPI/Taxonomy data, and DMEPOS accreditation records. CMS enrollment errors and lapsed accreditation are immediate grounds for payment suspension. Standardize documentation at the point of intake. Create mandatory intake checklists that capture SWO, referring provider details, medical necessity rationale, beneficiary signature/authorization, and delivery/POD info. Store these documents in searchable, time-stamped electronic records. Refer to DME MAC and MAC-region checklists for the exact documentation required by item. Map clinical criteria to billing codes. Maintain a brief clinical-to-code map for high-risk items (power mobility devices, oxygen, complex rehabilitative equipment). Cross-reference the CMS Master List and product-specific service requirements to avoid billing excluded items or insufficiently documented claims. Train staff regularly and test knowledge. Front-line intake staff and billers should receive quarterly refreshers on SWO requirements, proof of delivery, and beneficiary authorizations. Run periodic chart audits to identify recurring documentation gaps before an external auditor does. Use technology for retention and retrieval. Implement a records-retention policy aligned with CMS and MAC guidance, and employ searchable EHR or document management solutions so you can respond to Additional Documentation Requests (ADRs) promptly. Even the best-prepared suppliers get audited. What matters is your response. Acknowledge and triage immediately. Confirm the identity of the auditor and the scope of the request. Only accept legitimate requests through the channels specified by CMS or your MAC; beware of phishing. (MAC and CMS websites list legitimate communications.) Assemble a response team. Assign a lead (compliance officer or senior manager), the biller who handled the claim, the clinician for clinical questions, and legal or external counsel if exposure is large. Keep communications centralized and documented. Prioritize requests using risk and volume. Start with high-value claims and any items where policy is explicit (e.g., power mobility device repairs, oxygen). OIG audits frequently flag expensive categories; tackle these first. Provide exactly what's requested — no more, no less. Over-sharing may create new lines of inquiry. Prepare a clean, indexed package. For ADRs from RACs or MACs, respond within the stated timeframe and follow the ADR formatting guidance on the MAC portal. Document every interaction. Log phone calls, emails, uploads, and internal decisions. If you make voluntary refunds or adjustments, do so through standard claim adjustment procedures and preserve evidence of the action. If you disagree with a determination, use the MAC/RAC appeals process. Common successful appeals hinge on clear documentation that proves medical necessity or corrects a misunderstanding (e.g., updated SWO vs. original claim). If systemic issues caused the denial, quickly implement corrective action plans and document training/controls to mitigate further liability. One-time fixes are insufficient. Build an audit-ready culture: Monthly internal audits: Sample claims, focusing on top revenue items and recent policy changes. Sample claims, focusing on top revenue items and recent policy changes. Policy watch: Assign responsibility to monitor CMS, MAC, and OIG publications for new guidance or audit trends. (Subscribe to MAC listservs; CMS posts DMEPOS rules and updates.) Assign responsibility to monitor CMS, MAC, and OIG publications for new guidance or audit trends. (Subscribe to MAC listservs; CMS posts DMEPOS rules and updates.) Key performance indicators (KPIs): Track ADR turnaround time, percent of claims with complete SWOs, and audit recoupment dollars by month. Track ADR turnaround time, percent of claims with complete SWOs, and audit recoupment dollars by month. External reviews: Consider an annual external compliance audit or targeted coding review from a specialist familiar with DME audits. If you use third-party billers or clinicians who order DME, ensure contracts require compliance with documentation standards and give you audit access to records. Outsourced relationships remain your responsibility — vendors must conform to your policies and respond under your oversight. If you're evaluating dme billing services, require proof of experience with MAC/RAC audits, sample documentation processes, and references. (One clear performance condition: how they handle ADRs and appeals.) OIG and CMS audits consistently reveal a few recurring themes: lack of clinical justification, insufficient proof of delivery, billing during excluded periods (inpatient/hospice), and failure to meet product-specific requirements. These are actionable — close those gaps and you materially reduce audit exposure. Confirm PECOS enrollment and DMEPOS accreditation are active and documentation stored. Run a four-week sample audit of high-risk codes and correct deficiencies. Update intake checklists to always capture SWO, beneficiary authorization, and POD. Subscribe to your MAC's updates and the CMS DMEPOS quality standards page; assign someone to review and summarize changes weekly. Navigating DME billing audits requires a mix of tactical readiness and strategic change. By standardizing documentation, training staff, using technology for retention and quick retrieval, and staying current with CMS/MAC/OIG guidance, providers can turn audits from existential threats into manageable compliance events. The more you anticipate audit triggers and institutionalize best practices, the less disruptive — and costly — an audit will be. TIME BUSINESS NEWS
Yahoo
6 hours ago
- Yahoo
Trump administration tiptoes into testing prior authorization in traditional Medicare
Traditional Medicare plan holders have typically not had to wait for prior authorization before receiving medical treatment. Until now. The Centers for Medicare & Medicaid Services (CMS) recently announced a new program to test prior authorization requirements for certain services in six states starting Jan. 1. The states — New Jersey, Ohio, Oklahoma, Texas, Arizona, and Washington — will apply prior authorization evaluations to more than a dozen services. CMS says the pilot program is intended to root out 'fraud, waste, and abuse,' but as Medicare Advantage members know well, prior authorization can lead to frustrating delays in care. How it works CMS will contract with private companies to deploy 'enhanced technologies, including artificial intelligence (AI)' to conduct the authorization reviews. It won't apply to in-patient or emergency services or treatments 'that would pose a substantial risk to patients if significantly delayed,' according to a CMS press release. Specific services that will require prior authorization are skin and tissue substitutes, electrical nerve stimulator implants, and knee arthroscopy. There is genuine concern about the costs of some of these items and services. A recent New York Times article highlighted pricey medical products, including paper-thin bandages made of dried bits of placenta, for Medicare patients. The Biden administration had approved a plan to limit Medicare's coverage of the bandages, known as skin substitutes, which were reportedly being sold for roughly $10,000 per square inch. An updated Medicare policy proposes setting a significantly lower payment rate. The new prior authorization program 'is focused on reducing wasteful spending, which is an important goal for Medicare,' Jeffrey Marr, a health economist at the Brown University School of Public Health, told Yahoo Finance. 'I expect that the use of prior authorization in this model is likely to reduce the overall level of Medicare spending,' he said. 'Selecting potentially low-value services is a critical part of setting up a well-functioning prior authorization system.' The key question for CMS to address is whether prior authorization can work in traditional Medicare in a way that does not deny or discourage high-value care that improves beneficiaries' health, Marr said. One red flag: 'The companies that will make the prior authorization decisions will be paid a percentage of the savings that they generate for Medicare. This creates an incentive for participants to deny a high share of services,' he said. Sign up for the Mind Your Money weekly newsletter By subscribing, you are agreeing to Yahoo's Terms and Privacy Policy Prior authorizations are part of the Medicare landscape How often do prior authorizations pop up for seniors with Medicare and Medicare Advantage plans? In traditional Medicare, services that often require prior authorization include certain outpatient hospital services, non-emergency ambulance transport, and durable medical equipment. For 2023, under 400,000 prior authorization reviews for traditional Medicare beneficiaries were submitted to CMS, according to KFF data. Medicare Advantage plans, which are offered by private insurers, are a different story. Almost all Medicare Advantage enrollees — 99% according to KFF research — must receive prior authorization for some services. These are typically higher-cost services, such as inpatient hospital stays, skilled nursing facility stays, chemotherapy, and other drugs. That common practice, combined with AI used to scan these requests, is a thorny issue. 'Prior authorization processes and requirements, including the use of artificial intelligence to review requests, may result in administrative hassles for providers, delays for patients in receiving necessary care, and in some instances, denials of medically necessary services, such as post-acute care,' according to Jeannie Fuglesten Biniek, co-author of the KFF report. To allay that fear, CMS noted in the announcement: 'While technology will support the review process, final decisions that a request for one of the selected services does not meet Medicare coverage requirements will be made by licensed clinicians, not machines.' The prior authorization program will not alter Medicare coverage or payment rules, for now, but other services may be added later. There has been pushback. More than a dozen members of Congress sent a letter on Aug. 7 to CMS administrator Dr. Memet Oz to urge him to 'put patients and providers first by cancelling' the model and requested more details about how the program will be implemented. 'The use of prior authorization in Medicare Advantage shows us that, in practice, [this proposal] will likely limit beneficiaries' access to care, increase burden on our already overburdened healthcare workforce, and create perverse incentives to put profit over patients,' the lawmakers wrote.A pivot in MA authorization In an odd juxtaposition, a week prior to trumpeting this new Medicare pre-authorization model, the administration announced that it had a non-binding commitment from insurance plans to reduce prior authorization in Medicare Advantage. In late June, the Department of Health and Human Services announced an initiative coordinated with companies including Aetna, Blue Cross Blue Shield, Humana, and UnitedHealthcare, to streamline prior authorization processes for patients covered by Medicare Advantage. Under the initiative, electronic prior authorization requests would become standardized by 2027. 'Pitting patients and their doctors against massive companies was not good for anyone,' US Health and Human Services Secretary Robert F. Kennedy, Jr. said in a statement. 'We are actively working with industry to make it easier to get prior authorization for common services such as diagnostic imaging, physical therapy, and outpatient surgery.' Oz added: 'These commitments represent a step in the right direction toward restoring trust, easing burdens on providers, and helping patients receive timely, evidence-based care.' Kerry Hannon is a Senior Columnist at Yahoo Finance. She is a career and retirement strategist and the author of 14 books, including the forthcoming "Retirement Bites: A Gen X Guide to Securing Your Financial Future," "In Control at 50+: How to Succeed in the New World of Work," and "Never Too Old to Get Rich." Follow her on Bluesky. Sign up for the Mind Your Money newsletter
Yahoo
6 hours ago
- Yahoo
Trump administration tiptoes into testing prior authorization in traditional Medicare
Traditional Medicare plan holders have typically not had to wait for prior authorization before receiving medical treatment. Until now. The Centers for Medicare & Medicaid Services (CMS) recently announced a new program to test prior authorization requirements for certain services in six states starting Jan. 1. The states — New Jersey, Ohio, Oklahoma, Texas, Arizona, and Washington — will apply prior authorization evaluations to more than a dozen services. CMS says the pilot program is intended to root out 'fraud, waste, and abuse,' but as Medicare Advantage members know well, prior authorization can lead to frustrating delays in care. How it works CMS will contract with private companies to deploy 'enhanced technologies, including artificial intelligence (AI)' to conduct the authorization reviews. It won't apply to in-patient or emergency services or treatments 'that would pose a substantial risk to patients if significantly delayed,' according to a CMS press release. Specific services that will require prior authorization are skin and tissue substitutes, electrical nerve stimulator implants, and knee arthroscopy. There is genuine concern about the costs of some of these items and services. A recent New York Times article highlighted pricey medical products, including paper-thin bandages made of dried bits of placenta, for Medicare patients. The Biden administration had approved a plan to limit Medicare's coverage of the bandages, known as skin substitutes, which were reportedly being sold for roughly $10,000 per square inch. An updated Medicare policy proposes setting a significantly lower payment rate. The new prior authorization program 'is focused on reducing wasteful spending, which is an important goal for Medicare,' Jeffrey Marr, a health economist at the Brown University School of Public Health, told Yahoo Finance. 'I expect that the use of prior authorization in this model is likely to reduce the overall level of Medicare spending,' he said. 'Selecting potentially low-value services is a critical part of setting up a well-functioning prior authorization system.' The key question for CMS to address is whether prior authorization can work in traditional Medicare in a way that does not deny or discourage high-value care that improves beneficiaries' health, Marr said. One red flag: 'The companies that will make the prior authorization decisions will be paid a percentage of the savings that they generate for Medicare. This creates an incentive for participants to deny a high share of services,' he said. Sign up for the Mind Your Money weekly newsletter By subscribing, you are agreeing to Yahoo's Terms and Privacy Policy Prior authorizations are part of the Medicare landscape How often do prior authorizations pop up for seniors with Medicare and Medicare Advantage plans? In traditional Medicare, services that often require prior authorization include certain outpatient hospital services, non-emergency ambulance transport, and durable medical equipment. For 2023, under 400,000 prior authorization reviews for traditional Medicare beneficiaries were submitted to CMS, according to KFF data. Medicare Advantage plans, which are offered by private insurers, are a different story. Almost all Medicare Advantage enrollees — 99% according to KFF research — must receive prior authorization for some services. These are typically higher-cost services, such as inpatient hospital stays, skilled nursing facility stays, chemotherapy, and other drugs. That common practice, combined with AI used to scan these requests, is a thorny issue. 'Prior authorization processes and requirements, including the use of artificial intelligence to review requests, may result in administrative hassles for providers, delays for patients in receiving necessary care, and in some instances, denials of medically necessary services, such as post-acute care,' according to Jeannie Fuglesten Biniek, co-author of the KFF report. To allay that fear, CMS noted in the announcement: 'While technology will support the review process, final decisions that a request for one of the selected services does not meet Medicare coverage requirements will be made by licensed clinicians, not machines.' The prior authorization program will not alter Medicare coverage or payment rules, for now, but other services may be added later. There has been pushback. More than a dozen members of Congress sent a letter on Aug. 7 to CMS administrator Dr. Memet Oz to urge him to 'put patients and providers first by cancelling' the model and requested more details about how the program will be implemented. 'The use of prior authorization in Medicare Advantage shows us that, in practice, [this proposal] will likely limit beneficiaries' access to care, increase burden on our already overburdened healthcare workforce, and create perverse incentives to put profit over patients,' the lawmakers wrote.A pivot in MA authorization In an odd juxtaposition, a week prior to trumpeting this new Medicare pre-authorization model, the administration announced that it had a non-binding commitment from insurance plans to reduce prior authorization in Medicare Advantage. In late June, the Department of Health and Human Services announced an initiative coordinated with companies including Aetna, Blue Cross Blue Shield, Humana, and UnitedHealthcare, to streamline prior authorization processes for patients covered by Medicare Advantage. Under the initiative, electronic prior authorization requests would become standardized by 2027. 'Pitting patients and their doctors against massive companies was not good for anyone,' US Health and Human Services Secretary Robert F. Kennedy, Jr. said in a statement. 'We are actively working with industry to make it easier to get prior authorization for common services such as diagnostic imaging, physical therapy, and outpatient surgery.' Oz added: 'These commitments represent a step in the right direction toward restoring trust, easing burdens on providers, and helping patients receive timely, evidence-based care.' Kerry Hannon is a Senior Columnist at Yahoo Finance. She is a career and retirement strategist and the author of 14 books, including the forthcoming "Retirement Bites: A Gen X Guide to Securing Your Financial Future," "In Control at 50+: How to Succeed in the New World of Work," and "Never Too Old to Get Rich." Follow her on Bluesky. Sign up for the Mind Your Money newsletter Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
